2014 Updates and Recommendations from the CLSI for Antimicrobial Susceptibility Testing and Reporting (by CACMLE) (Online Course)

Janet Hindler, MCLS, MT(ASCP), F(AAM)

See all available courses »

Continuing Education Credits

Objectives

  • List some of the new recommendations for antimicrobial susceptibility testing and reporting published in CLSI document M100-S24.
  • Describe how to best interpret susceptibility test results for cephalosporins with Enterobacteriaceae and carbapenems with Acinetobacter.
  • Describe a strategy for optimizing QC testing based on modified CLSI recommendations.

Course Outline

  • PowerPoint Slides
      • 2014 Updates & Recommendations from the Clinical and Laboratory Standards Institute (CLSI) for Antimicrobial Susceptibiltiy Testing (AST) and Reportin...
      • Learning Objectives
      • 2014 CLSI AST Standards
      • Summary of Changes
      • Breakpoint Additions / Revisions
      • Verification of ASTs
      • Enterobacteriaceae: Cefazolin & Cephalothin
      • M100 - S42. Glossary 1.
      • M100 - S42. Glossary II.
      • When might cefazolin be prescribed?
      • M100 - S42. Table 1A
      • Enterbacteriaceae: Cefazolin
      • Enterbacteriaceae: Cefazolin Footnote
      • When might oral cephalosporins be prescribed for UTIs?
      • Cefazolin % Susceptible (urine isolates - UCLA)
      • Cefazolin - UCLA Protocol
      • Cefazolin % Susceptible (non-urine isolates - UCLA)
      • Exercise 1
      • Specimen: Urine; Diagnosis: Cystitis
      • Final Report with Comment
      • Escherichia coli % Susceptible
      • Enterobacteriaceae: Cefepime
      • Cefepime (extended-spectrum cephalosporins)
      • Cefepime
      • Cefepime MIC Breakpoints
      • "Drug Exposure"
      • Dosing Options
      • M100 - S24. Table 2A and Appendix E
      • Intermediate Versus Susceptible Dose Dependent (SDD) Categories
      • Why SDD and not Intermediate?
      • Cefepime % Susceptible
      • Implementing new Cefepime Breakpoints?
      • Specimen: Blood; Diagnosis: Bacteremia
      • Exercise 2
      • Specimen: Blood; Diagnosis: Bacteremia
      • Acinetobacter Species
      • Acinetobacter species MIC Breakpoints
      • Antibiotic Resistance Threats: Acinetobacter species
      • Acinetobacter Healthcare Associated Infections in the United States
      • Specimen: Bronchoalveolar Lavage; Diagnosis: Pneumonia
      • Table 1A. Agents to Consider for Testing & Reporting
      • Acinetobacter species: SENTRY North America 2012
      • Acinetobacter baumannii Carbapenem Resistance Mechanisms
      • Carbapenemases: Molecular Classes
      • M11 - S24. App. B2. Intrinsic Resistance
      • Acinetobacter baumannii
      • Acinetobacter baumannii % Susceptible
      • Multidrug-Resistant (MDR) Acinetobacter baumannii % Susceptible
      • Acinetobacter species: Minocycline
      • QA/QC of AST
      • Ensuring Quality of AST Results
      • Newer Developments in CLSI AST QC Recommendations
      • Routine QC Recommendations
      • Acceptable QC Ranges: Carbapenems
      • "Routine" QC Testing Changes
      • Convert from Daily to Weekly QC
      • Convert from Daily to Weekly QC: Data Sources
      • Weekly QC Reports: Out-of Range Error Categories
      • Weekly QC: Out-of-range (Error Not Identifiable)
      • Multilevel AST Educational Resources
      • Additional Resources
      • EUCAST Expert Rules
      • Summary (1)
      • Summary (2)
      • The End



Slide 1


Slide 12


Slide 15


Slide 23


Slide 26